BB's Stock Haven

[TPX]

$MCET TOP PATENTS!

Any proprietary protection that we can obtain and maintain will be important to our business.

On September 7, 2005, MCTI, entered into an Asset Contribution Agreement (the “Asset Contribution Agreement”) with MultiCell, Alliance Pharmaceutical Corp. (“Alliance”), and Astral, Inc. (“Astral,” and together with Alliance, (“Transferors”). Pursuant to the Asset Contribution Agreement, MCTI issued 490,000 shares of common stock to Alliance in consideration for the acquisition of certain assets and the assumption of certain liabilities relating to Transferors’ business. The intellectual property acquired by MCTI includes ten United States and 20 foreign issued and pending patents and patent applications related to chimeric antibody technology, treatment of Type 1 diabetes, T-cell tolerance, TLR technology, dendritic cells, dsRNA technology and immunosuppression.

In December 2003, we acquired the exclusive worldwide rights to US Patent # 6,129,911, for Liver Stem Cells from Rhode Island Hospital. We agreed to pay an annual license fee of $20,000 for the first three years of the applicable license agreement and $10,000 per annum thereafter until a product is developed. Once a product is developed, if ever, the annual license fee will end and we will pay Rhode Island Hospital a five percent royalty on net sales of any product we sell covered by the patent until we pay an aggregate of $550,000 in royalties and a two percent royalty thereafter until the expiration of the patent. The expiration date of this patent is October 10, 2017.

In April 2005, we were granted US Patent # 6,872,389 for the liver stem cell invention of Dr. Ron Faris, MultiCell’s former Senior Vice President and Chief Scientific Officer. This patent contains 24 claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to our adult stem cell portfolio. The expiration date of this patent is July 8, 2019.


We have an exclusive, long-term license agreement with Rhode Island Hospital for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs):

US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;
US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;
US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017; and
US Patent #6,872,389 Liver Stem Cell expires on July 8, 2019.

If we generate revenues and pay royalties, the annual license fee structure does not apply. Our agreement with Rhode Island Hospital provides that we would pay a five percent royalty until we pay Rhode Island Hospital an aggregate of $550,000. After that, the royalty percentage decreases to two percent for the life of the patents.

On November 3, 2003, Xenogenics was notified by the United States Patent and Trademark Office that its patent application for an “Artificial Liver Apparatus And Method”, the Sybiol® Synthetic Bio-Liver Device, would be allowed. United States patent 6,858,146 was issued in 2005. The expiration date of this patent is February 22, 2026. The Sybiol® trademark is registered in the United States Patent and Trademark Office, number 2,048,080.

Xenogenic’s Ideal BioStent™ is covered by patents owned by Rutgers and exclusively licensed to Xenogenics. The license between Xenogenics and Rutgers includes exclusive license rights and option to 23 issued patents and 61 patent applications with claims encompassing the basic design and synthesis of certain bioabsorbable polymers and their use in combination with drugs in medical devices.

The patent estate acquired by Xenogenics as part of its acquisition of the Ideal BioStent™ includes one issued U.S. patent and four patent applications. This patent estate covers the composition and synthesis of the Ideal BioStent™ proprietary bioabsorbable polymers, admixing of drugs and bioabsorbable polymers for therapeutic applications, and the use of these bioabsorbable polymers in stents and other medical devices.

http://www.sec.gov/Archives/edgar/data/811779/000114420414012288/v367480_10k.htm

####################################################################################################################################

US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015

Isolation and culture of porcine hepatocytes US 6017760 A

ABSTRACT

A perfusion device such as a liver assist device containing a housing defining a perfusion inlet and a perfusion outlet, a porous membrane structure mounted within said housing to define a perfusion compartment and an adjacent hepatocyte compartment, and porcine hepatocytes isolated from a porcine liver by retrograde perfusion.

http://www.google.com/patents/US6017760

US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019

Immortalized hepatocytes US 6107043 A

ABSTRACT

The invention features a virally-immortalized mammalian hepatocyte, which is derived from a normal liver cell, has differentiated hepatocyte-specific metabolic activity, has the ability to proliferate, and is nontumorigenic after prolonged culture.

http://www.google.com/patents/US6107043

US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017

Liver stem cell US 6129911 A

ABSTRACT

The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.

http://www.google.com/patents/US6129911

US Patent #6,872,389 Liver Stem Cell expires on July 8, 2019

Liver stem cell US 6872389 B1

ABSTRACT

The invention provides methods of isolating a primary liver stem cell by identifying a cell doublet containing a hepatocytes and the stem cell and isolating the doublet from liver tissue.

http://www.google.com/patents/US6872389

US Patent #6,858,146 Artificial Liver Apparatus And Method

Artificial liver apparatus and method US 6858146 B1

ABSTRACT

Artificial liver devices and methods for using the devices to purify a biological fluid are disclosed. The methods include the use of living hepatocytes (23) which are either unattached or attached to inert carriers and suspended in a cell culture medium which circulates in the devices with the hepatocytes (23). Blood or plasma passes on one side (7?) of semi-permeable membranes, on the other side (7) of which is the cell culture medium and across which is a concentration and/or pressure gradient. Solutes diffusing across the membrane into the cell culture medium are metabolized by the hepatocytes (23) and/or captured by additional removal means (4). Those undesirable substances which do not diffuse out of the blood or plasma into the hepatocyte containing culture medium are captured by additional removal means (50).

http://www.google.com/patents/US6858146

####################################################################################################################################

MCET Multicell Technologies Partners

AMARIN / CORNING / PFIZER

http://www.multicelltech.com/about-us/partners/

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc.

US Patent 6,737,057: Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US Patent 6,129,911: Liver stem cell
US Patent 6,872,389: Liver stem cell
US Patent 6,017,760: Isolation and culture of porcine hepatocytes
US Patent 6,107,043: Immortalized hepatocytes
US Patent 5,043,260: Perfusion device with hepatocytes
US Patent 4,795,459: Implantable Prosthetic Device (endothelial)
US Patent 6,858,146: Artificial Liver Apparatus and Method (Trademarked as the SybiolR synthetic bio-liver)
US Patent 7,935,528 The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
US Patent 7,566,567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1: IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: Use of cell lines to produce active therapeutic proteins
EP1685252A4: Use of cell lines to produce active therapeutic proteins
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: Use of cell lines to produce active therapeutic proteins
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 Use of cell lines to produce active therapeutic proteins
WO05034876A2 Use of cell lines to produce active therapeutic proteins
CA2541380A1 Use of cell lines to produce active therapeutic proteins
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Xenogenics.

When Xenogenics acquired the assets of Bioabsorbable Therapeutics, Inc., it acquired and continues to support issued U.S. patent 7,674,285: Polyanhydride polymers and their uses in biomedical devices. This process is incorporated in and trademarked as the Ideal Bio-StentR.

MultiCell ImmunoTherapeutics.

Below is a listing of the intellectual properties of which Astral, Inc. is the Assignee. This intellectual property is now owned by MultiCell Immunotherapeutics resulting from the purchase agreement between MultiCell Technologies, Inc. and Alliance Pharmaceuticals, Inc.

US20120189645A1:Compositions and methods to treat and control tumors.
CN100376594C: Double-chain RNA and method to initiate, enhance or adjust immunomodulatory or immune response.
CN1795274A: Selected RNA motifs to include cell death and/or apoptosis.
CN1780848A: Compositions and methods to initiate or enhance antibody and
major-histocompatibility class i or class ii-restricted t cell responses by
using immunomodulatory, non-coding RNA motifs.
WO04087877A3: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1703427A: Methods and compositions to generate and control the effector profile of Tcells by simultaneous loading and activation of selected subsets of antigen presenting cells .
WO04087877A2: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
WO04027049B1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO04027049A3: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595B1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
WO04027049A2: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A3: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
CA2520181A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CA2499066A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
AU4225480A1: Selected RNA motifs to include cell death and/or apoptosis.
AU3276932A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A2: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
CA2479187A1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
AU3218181A1: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
US7566567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: Use of cell lines to produce active therapeutic proteins
EP1685252A4: Use of cell lines to produce active therapeutic proteins
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: Use of cell lines to produce active therapeutic proteins
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 Use of cell lines to produce active therapeutic proteins
WO05034876A2 Use of cell lines to produce active therapeutic proteins
CA2541380A1 Use of cell lines to produce active therapeutic proteins
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins

http://www.multicelltech.com/therapeutic-pipeline/published-patents/